China bio-tech Company WILLINGMED raised tens of millions of Yuan in a series angel round funding led exclusively by Mifang Capital. The investment will be used for the layout of a series of clinical infection pathogen diagnosis products and the development and registration of genomic testing related products.
WILLINGMED focus on the detection of pathogenic microorganisms in clinical infection. The company has built two technology platforms which are ultra-broad spectrum metagenomics and ultra-fast microfluidic chip, for the layout of a series of clinical infection pathogen diagnosis products, so as to cope with the pain points of accurate diagnosis of pathogens in clinical infectious diseases.
South Africa Today
Read more at VolaNews
